Clinical trials: Paclitaxel, completed
Lung Cancer
Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs.
- Trial name
- NCT00062010
- Testing
- interferon alpha, 13-cis-retinoic acid, paclitaxel
- Where
- 73 sites in United States
- Volunteers
- 37 people
- Sponsor
- Eastern Cooperative Oncology Group
Estrogen Receptor Negative, Estrogen Receptor Positive
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
This randomized phase III trial studies the side effects and how well different chemotherapy regimens with or without bevacizumab work in treating patients with stage IIIC or stage IV breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT00785291
- Testing
- Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis
- Where
- 704 sites in United States, Puerto Rico
- Volunteers
- 799 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
This is a phase I study to evaluate the safety and define the pharmacokinetic (PK) profile of orally administered reparixin in combination with paclitaxel in HER 2 (Human epidermal growth factor receptor-2) negative metastatic…
- Trial name
- NCT02001974
- Testing
- Paclitaxel+Reparixin
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Dompé Farmaceutici S.p.A
Non Small Cell Lung Cancer
Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV…
- Trial name
- NCT03081689
- Testing
- Nivolumab 360 mg, Paclitaxel 200mg/m2, Carboplatin AUC 6
- Where
- 24 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Spanish Lung Cancer Group
Breast Neoplasms
Pembrolizumab and Paclitaxel in Hypermutated Breast Cancer
Abbreviated Title: Pembrolizumab in hypermutated breast cancer Trial Phase: II Clinical Indication: Hormone receptor-positive metastatic breast cancer Trial Type: Interventional Type of control: None Route of administration…
- Trial name
- NCT03492918
- Testing
- Pembrolizumab, paclitaxel
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Yonsei University
Breast Cancer
Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer
The purpose of this study is to determine if the investigators are able to locate and measure certain characteristics in breast cancer tumors that have been treated with paclitaxel that may correlate to how well the cancer will…
- Trial name
- NCT01263613
- Testing
- tumor biopsy and blood draw
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Wisconsin, Madison
Peripheral Arterial Disease, Claudication
Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease
The DEFINITIVE AR study is a prospective, multi-center, randomized pilot study evaluating the use of either the TurboHawk™ or SilverHawk® plaque excision systems followed by treatment with the Cotavance™ drug-eluting balloon…
- Trial name
- DEFINITIVE AR (NCT01366482)
- Testing
- Cotavance Drug-Eluting Balloon, TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon
- Where
- Belgium
- Volunteers
- 121 people
- Sponsor
- Medtronic Endovascular
Adult Type Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
This phase II trial studies the effectiveness of paclitaxel in treating patients who have ovarian stromal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adult Type Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules
- Trial name
- NCT00006227
- Testing
- Paclitaxel
- Where
- 98 sites in United States, Japan
- Volunteers
- 31 people
- Sponsor
- Gynecologic Oncology Group
Breast Cancer, TNBC - Triple-Negative Breast Cancer
First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients
To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin plus carilizumab as first-line treatment in patients with metastatic triple-negative breast cancer.
- Trial name
- NCT04537286
- Testing
- nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fudan University
Lung Cancer
Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276588
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Endometrial Carcinoma
Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
The purpose of this study is to find out whether the addition of a drug called Avastin (avastin) to the two-drug combination of carboplatin and paclitaxel shrinks tumors better than the two-drug combination alone in the treatment…
- Trial name
- NCT00879359
- Testing
- carboplatin, paclitaxel, and bevacizumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II trial is studying how well ABI-007 works in treating patients with persistent or recurrent cervical cancer. Drugs used in chemotherapy, such as ABI-007, work in different ways to stop the growth of tumor cells…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00309959
- Testing
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis
- Where
- 26 sites in United States
- Volunteers
- 37 people
- Sponsor
- Gynecologic Oncology Group
Non-small Cell Lung Cancer, Stage II-IIIA
Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1013. The purpose of this neoadjuvant and adjuvant study is to evaluate the efficacy and safety of Serplulimab and…
- Conditions
- Non-small Cell Lung Cancer, Stage II-IIIA, Immunotherapy, Neoadjuvant Therapy
- Trial name
- NCT05775796
- Testing
- Serplulimab and Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Neoplasms
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
This phase IB trial aims to identify anticancer activity of GSK3052230 in subjects with malignancies with abnormal dependence on FGF pathway signaling.
- Trial name
- NCT01868022
- Testing
- GSK3052230, paclitaxel, carboplatin
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 65 people
- Sponsor
- GlaxoSmithKline
Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer.
- Trial name
- TRIBECA (NCT02064829)
- Testing
- Nab-paclitaxel, IG-001
- Where
- 20 sites in United States, Georgia and 5 more
- Volunteers
- 111 people
- Sponsor
- Sorrento Therapeutics, Inc.
NSCLC
Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC
A randomized, double blind, multicenter phase3 study .
- Trial name
- NCT02954172
- Testing
- Bevacizumab in Combination With Paclitaxel/Carboplatin, IBI305 in Combination with Paclitaxel/Carboplatin
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Breast Cancer
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003972
- Testing
- filgrastim, sargramostim, busulfan
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Fred Hutchinson Cancer Center
Carcinoma, Squamous Cell of the Head and Neck
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus…
- Trial name
- NCT01166542
- Testing
- REOLYSIN, Carboplatin, Paclitaxel
- Where
- 77 sites in United States, Belgium and 11 more
- Volunteers
- 167 people
- Sponsor
- Oncolytics Biotech
Pancreatic Cancer
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
The main purpose of this study is to find out the dose of enzalutamide that can be safely given with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.
- Trial name
- NCT02138383
- Testing
- Enzalutamide, Gemcitabine, Nab-paclitaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
The primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor deoxyribonucleic acid (ctDNA) at Cycle 3 (ΔctDNA) is larger in…
- Trial name
- NCT05446870
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- 45 sites in United States, Belgium and 9 more
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.